Tickers

1. Composite Trajectory Verdict

For a capital-intensive, cyclical nitrogen producer like CF, the income statement and cash flow statement carry the most weight because earnings volatility is driven by commodity price spreads (selling price vs. natural gas cost) and cash generation funds the heavy reinvestment cycle (maintenance capex, decarbonization projects, and shareholder returns).

Composite Trajectory: Mixed

The 2025 annual results show a sharp recovery from the 2024 trough but a mixed picture relative to the 2023 peak. Revenue ($7.084B) and gross margin ($2.724B) exceeded 2023 levels, and diluted EPS ($8.97) rose 14% above 2023 due to a 16% reduction in share count (10-K 2025-12-31, Consolidated Statements of Operations). However, net earnings attributable to common stockholders ($1.455B) remained 4.6% below 2023 ($1.525B) because noncontrolling interest claims grew 32% to $343M (10-K 2025-12-31, Consolidated Statements of Operations). Operating cash flow ($2.752B) returned to near-2023 levels ($2.757B), but capex nearly doubled to $950M (from $518M in 2024) driven by the Blue Point JV, and financing outflows stayed elevated at $1.484B due to $1.365B of share repurchases (10-K 2025-12-31, Consolidated Statements of Cash Flows). On the balance sheet, total debt rose 8% to $3.215B while stockholders' equity fell 3% to $4.838B as buybacks and dividends exceeded earnings attributable to common (10-K 2025-12-31, Consolidated Balance Sheets). The trajectory is therefore improving year-over-year from 2024 but has not fully surpassed the 2023 peak on a per-share-owner basis, and leverage has increased.

2. Red Flags

• Asset impairments recurred in 2025: $76M total ($25M Yazoo City AN upgrade area damage + $51M electrolyzer project abandonment) after zero impairments in 2024 and 2023 (10-K 2025-12-31, Consolidated Statements of Operations; Note 6).
• Share repurchases consumed 94% of earnings attributable to common: $1.365B of buybacks vs. $1.455B net earnings attributable to common stockholders in 2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows; Consolidated Statements of Operations).
• Debt increased while stockholders' equity declined: Long-term debt rose $244M to $3.215B (new $1B 2035 notes less $750M 2026 note redemption) while total stockholders' equity fell $147M to $4.838B (10-K 2025-12-31, Consolidated Balance Sheets; Consolidated Statements of Cash Flows).
• Noncontrolling interest earnings grew faster than consolidated earnings: NCI share rose 32% to $343M vs. 22% growth in consolidated net earnings, reducing the common shareholder portion (10-K 2025-12-31, Consolidated Statements of Operations).
• PLNL gas supply contract expired Jan 1, 2026: Only short-term extensions in place; loss of gas supply would trigger impairment of the $32M equity method investment (10-K 2025-12-31, Note 8).
• Yazoo City AN production idled until at least Q4 2026: Full-site outage removes AN and upgrade capacity; 2026 gross ammonia production guided ~9.5M tons vs. 10.1M tons in 2025 (10-K 2025-12-31, MD&A Consolidated Results; Note 6).
• Blue Point JV capital calls accelerating: $600M planned 2026 JV capex (CF share ~$240M) plus $150M CF-only infrastructure spend (10-K 2025-12-31, Liquidity and Capital Resources).
• Effective tax rate jumped to 19.7% from 16.2%: Driven by increases in unrecognized tax benefits under IRS audit (10-K 2025-12-31, MD&A Income Tax Provision).
• Customer advances fell 35% to $77M: Down from $118M at end-2024, reducing a key working capital funding source (10-K 2025-12-31, Consolidated Balance Sheets).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Revenue rebounded 19% to $7.084B in 2025 from $5.936B in 2024, surpassing the 2023 level of $6.631B, driven by a 19% rise in average selling price to $372/ton (10-K 2025-12-31, Consolidated Statements of Operations; MD&A Net Sales). Gross margin expanded to $2.724B (38.5%) from $2.056B (34.6%) in 2024, also above the 2023 margin of $2.545B (38.4%) (10-K 2025-12-31, Consolidated Statements of Operations). Operating earnings reached $2.300B, up 32% from 2024 and 3% above 2023 (10-K 2025-12-31, Consolidated Statements of Operations). However, net earnings attributable to common stockholders of $1.455B, while up 19% from 2024, remained 4.6% below the 2023 figure of $1.525B because noncontrolling interest claims rose to $343M from $259M (10-K 2025-12-31, Consolidated Statements of Operations). Diluted EPS of $8.97 exceeded both 2024 ($6.74) and 2023 ($7.87) due to a 10% year-over-year and 16% two-year reduction in diluted shares (162.2M vs. 180.7M vs. 193.8M) (10-K 2025-12-31, Consolidated Statements of Operations). Items affecting comparability totaled $76M pre-tax in 2025 (impairments, Ince sale loss, Blue Point costs, debt extinguishment) versus a net $16M gain in 2024 (10-K 2025-12-31, Items Affecting Comparability).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Operating cash flow recovered to $2.752B in 2025 from $2.271B in 2024, essentially matching the 2023 level of $2.757B (10-K 2025-12-31, Consolidated Statements of Cash Flows). The increase was driven by higher gross margin, partially offset by $200M less working capital contribution year-over-year (10-K 2025-12-31, MD&A Cash Flows). Investing outflows doubled to $933M from $469M, with capex jumping 83% to $950M (including $307M Blue Point JV spend) versus $518M in 2024 and $499M in 2023 (10-K 2025-12-31, Consolidated Statements of Cash Flows; MD&A Capital Spending). Financing outflows of $1.484B remained high, comprising $1.365B share repurchases, $326M dividends, $304M distributions to noncontrolling interests, offset by $999M debt proceeds and $291M JV partner contributions (10-K 2025-12-31, Consolidated Statements of Cash Flows). Cash and cash equivalents rose to $1.982B from $1.614B but stayed 2.5% below the 2023 year-end balance of $2.032B (10-K 2025-12-31, Consolidated Statements of Cash Flows). Free cash flow (operating minus capex) was $1.802B in 2025 vs. $1.753B in 2024 and $2.258B in 2023.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew 4.6% to $14.088B from $13.466B, led by a 23% increase in cash to $1.982B, 21% higher receivables ($488M), and 22% higher inventories ($383M) (10-K 2025-12-31, Consolidated Balance Sheets). PP&E was flat at $6.715B while goodwill was unchanged at $2.493B (10-K 2025-12-31, Consolidated Balance Sheets). Total liabilities rose 7.5% to $6.313B, with long-term debt up 8.2% to $3.215B (new 2035 notes net of 2026 note redemption) and current liabilities up 8.4% to $887M (10-K 2025-12-31, Consolidated Balance Sheets). Total equity increased 2.4% to $7.775B, but the composition shifted: noncontrolling interests grew 12.7% to $2.937B (including $293M Blue Point JV NCI) while stockholders' equity fell 2.9% to $4.838B as $1.353B of treasury stock purchases and $326M dividends exceeded $1.455B retained earnings (10-K 2025-12-31, Consolidated Balance Sheets; Consolidated Statements of Equity). The debt-to-equity ratio (long-term debt / total equity) rose to 0.41x from 0.39x; debt-to-stockholders'-equity rose to 0.66x from 0.60x (10-K 2025-12-31, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly income statement, cash flow, and balance sheet data for Q1-Q3 2025 and Q1-Q2 2026 (10-Q filings provided but content truncated in the supplied documents)
• Q3 2026 and Q4 2026 quarterly results (not yet filed)
• Segment-level quarterly revenue, gross margin, and volume trends
• Detailed debt maturity schedule beyond the 2026 note redemption described in the 10-K
• Working capital component trends (receivables, inventory, payables, advances) on a quarterly basis
• Blue Point JV capital call schedule beyond the disclosed 2026 estimate
• PLNL gas contract negotiation outcome post-January 1, 2026 expiration
• Yazoo City restart progress and cost updates beyond the "Q4 2026 at earliest" guidance